Skip to content
CompletedNot applicable

Study of the Effects of MDMA/Ecstasy on Water Regulation, Sleep, and Cognition.

NCT01053403 · 2C · California Pacific Medical Center Research Institute

Closed to entry
Status
Not accepting participants
Not applicable
Phase
12
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

The purpose of this study is to measure the effects of MDMA on sleep, mood, thinking, and how your body retains water. The researchers are interested in the effects that occur a few hours after taking MDMA as well as effects occurring over the next two days. We will study these effects in a standardized, controlled setting at the Clinical and Translational Science Institute (CTSI) Clinical Research Center (CRC) located at San Francisco General Hospital. The primary hypotheses are: 1. MDMA will induce sleep disruption, as indicated by comprehensive polysomnography, wrist actigraphy, and self-report sleep measures 2. MDMA will alter sodium and water homeostasis by either increasing or blunting the suppression of arginine vasopressin levels and decreasing free water excretion. Effects will be exacerbated by water loading. Secondary hypotheses: 1. Acutely, MDMA will increase both positive and negative arousal, and to increase sociability but not autonomy. 2. Acutely, MDMA will increase risk-taking and willingness to donate money to others in an economic decision making task. 3. MDMA will decrease the stressful effects of talking about a negatively-valenced autobiographical but will increase recall for details for these episodes. 4. MDMA will increase oxidative stress markers and possible ameliorating factors (e.g., ADMA). 5. The short form of the serotonin transported promoter region will be associated with greater acute and discontinuation effects of MDMA.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Time course, severity, and characteristics of MDMA discontinuation in experienced MDMA users given a known dose of MDMA

    Measured over 1 hour post dose through 48 hours post dose

  • Relate observed discontinuation effects to sleep data: polysomnography, wrist actigraphy, and self-report sleep measures.

    Measured over 1 hour post dose through 48 hours post dose

  • Assess the acute effects of MDMA on water and sodium homeostasis

    Measured over 1 hour post dose through 48 hours post dose

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 50 Years
Ages
All
Sex
Accepted
Healthy volunteers
Inclusion Criteria: * Healthy men or women aged 18 to 50 years. * If female: abstains from heterosexual sex, not of childbearing potential, or reports using an approved contraceptive. * Experienced with MDMA * Fluent in English. * Willing and able to give written consent. * Healthy without medical contraindications to MDMA administration determined by the following: medical history, physical examination, 12-lead EKG, hematology, blood chemistry, and urinalysis. * Blood liver transaminase elevations up to 3 times the upper limit of normal. * If female: negative pregnancy test at screening and at the beginning of each hospital admission. * Negative urine drug test at screening and prior to each potential MDMA administration. Exclusion Criteria: * Current enrollment in a MDMA, alcohol, or other drug treatment program or current legal problems relating to MDMA, alcohol, or other drug use, including awaiting trial or supervision by a parole or probation officer. * Participants with a past-history of using only low doses of MDMA * Currently trying to quit MDMA use. * Current dependence on any other psychoactive drug (including nicotine). * Significant physical or psychiatric illness that might impair the ability to safely complete the study or that might be complicated by the study drugs, including prior seizures (after age 8) or other active neurological disease or clinically significant abnormalities on physical examination or screening laboratory values. * Likelihood of needing medications to treat an illness during the study period. * Body Mass Index \> 30 or \< 18. * HIV seropositive by self-report. * If female: pregnancy or lactation. * History of serious adverse event or hypersensitivity to MDMA. * Currently taking any medication other than over-the-counter non-steroidal anti-inflammatories, topical medications, inhaled asthma therapy, and over-the-counter non-sedating antihistamines. * Male neck size ≥ 17 inches, female neck size ≥ 16 inches * Modified Mallampati class ≥ 3. * Recent travel within 3 days to or from a different time zone, other than Mountain Standard Time. * Any other medical or psychosocial condition that would preclude useful, safe, or consistent participation.

Where

1 study site

FacilityCityRegionCountry
CPMC Addiction & Pharmacology Research Laboratory (APRL)San FranciscoCaliforniaUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT01053403 on ClinicalTrials.gov →

Last updated in the registry 2013-05-31. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits